Ourania E Tsitsilonis

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/935102/ourania-e-tsitsilonis-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

1,328
citations

20
h-index

82
ext. papers

1,683
ext. citations

4.8
avg, IF

L-index

#	Paper	IF	Citations
76	4th Summer School in Immuno-Oncology, July 1st-3rd, 2021, Athens, Greece. <i>Frontiers in Bioscience</i> , 2021 , 26, 1373-1382		
75	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Clinical Infection. <i>Frontiers in Immunology</i> , 2021 , 12, 746203	8.4	2
74	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021 , 9,	5.3	6
73	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021 , 9,	4.9	7
72	Clusterin overexpression in mice exacerbates diabetic phenotypes but suppresses tumor progression in a mouse melanoma model. <i>Aging</i> , 2021 , 13, 6485-6505	5.6	1
71	Ethalassemia minor is a beneficial determinant of red blood cell storage lesion. <i>Haematologica</i> , 2021 ,	6.6	6
70	Acute administration of the olive constituent, oleuropein, combined with ischemic postconditioning increases myocardial protection by modulating oxidative defense. <i>Free Radical Biology and Medicine</i> , 2021 , 166, 18-32	7.8	7
69	Dual RNA-Seq Enables Full-Genome Assembly of Measles Virus and Characterization of Host-Pathogen Interactions. <i>Microorganisms</i> , 2021 , 9,	4.9	2
68	Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
67	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 28, 19-23	2.7	15
66	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021 , 28, 9	13.3	52
65	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 1-8	2.7	1
64	Synthesis, Biological Evaluation and Stability Studies of Some Novel Aza-Acridine Aminoderivatives. <i>Molecules</i> , 2020 , 25,	4.8	1
63	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	6
62	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020 , 10, 860	5.3	16
61	Malignancy Grade-Dependent Mapping of Metabolic Landscapes in Human Urothelial Bladder Cancer: Identification of Novel, Diagnostic, and Druggable Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
60	Visualization and analysis of the interaction network of proteins associated with blood-cell targeting autoimmune diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 165714	6.9	2

(2018-2020)

59	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 25-25	2.2	О
58	In Vitro Immunodetection of Prothymosin Alpha in Normal and Pathological Conditions. <i>Current Medicinal Chemistry</i> , 2020 , 27, 4840-4854	4.3	2
57	Cytotoxicity and Anti-cancer Activity of the Genus L. Current Medicinal Chemistry, 2020, 27, 6910-6925	4.3	2
56	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2020 , 13,	6.2	18
55	Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020 , 25, 273-285	2.6	7
54	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020 , 10,	3	20
53	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12,	6.6	3
52	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	9
51	Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 8010-8018	5.6	2
50	Antiproliferative Activity of (-)-Rabdosiin Isolated from L. <i>Medicines (Basel, Switzerland)</i> , 2019 , 6,	4.1	7
49	The effect of intrauterine growth on leukocyte telomere length at birth. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019 , 32, 3948-3953	2	2
48	4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1391-1400	7.4	1
47	Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential. <i>Heliyon</i> , 2019 , 5, e02616	3.6	1
46	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019 , 3, e300	0.3	11
45	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019 , 3, 3002-3009	7.8	22
44	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. <i>Cancers</i> , 2019 , 11,	6.6	2
43	Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. <i>Redox Biology</i> , 2018 , 16, 169-178	11.3	23
42	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018 , 9, 17797-17809	3.3	7

41	2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15-17, 2016, Athens, Greece. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 153-159	7.4	
40	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018 , 8, 46	7	35
39	In vivo biodistribution and imaging studies with a Tc-radiolabeled derivative of the C-terminus of prothymosin alpha in mice bearing experimentally-induced inflammation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017 , 113, 188-197	5.7	2
38	New semi-synthetic analogs of oleuropein show improved anticancer activity in vitro and in vivo. European Journal of Medicinal Chemistry, 2017 , 137, 11-29	6.8	18
37	Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. <i>Vaccine</i> , 2017 , 35, 4330-4338	4.1	7
36	A fragment of the alarmin prothymosin las a novel biomarker in murine models of bacteria-induced sepsis. <i>Oncotarget</i> , 2017 , 8, 48635-48649	3.3	2
35	Prothymosin Alpha: An Alarmin and More. Current Medicinal Chemistry, 2017, 24, 1747-1760	4.3	15
34	A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptides. <i>Cellular Immunology</i> , 2016 , 302, 32-40	4.4	3
33	Immune responses of a wall lizard to whole-body exposure to radiofrequency electromagnetic radiation. <i>International Journal of Radiation Biology</i> , 2016 , 92, 162-8	2.9	3
32	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016 , 4, 261	3.2	167
31	A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer. <i>Anticancer Research</i> , 2016 , 36, 3373-82	2.3	3
30	Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils. <i>International Journal of Pharmaceutics</i> , 2015 , 486, 1-12	6.5	13
29	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015 , 25, 2621-3	2.9	2
28	Immunophenotypic analysis reveals heterogeneity and common biologic aspects in monoclonal B-cell lymphocytosis. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 210-21	5	9
27	In vitro exposure of NK-92 cells to serum from patients with non-small cell lung cancer impairs their cytotoxicity. <i>Anticancer Research</i> , 2015 , 35, 1543-8	2.3	3
26	ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models. <i>International Journal of Oncology</i> , 2014 , 45, 1457-68	4.4	22
25	Prothymosin and a prothymosin derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes. <i>BMC Immunology</i> , 2013 , 14, 43	3.7	18
24	The C-terminal decapeptide of prothymosin ls responsible for its stimulatory effect on the functions of human neutrophils in vitro. <i>International Immunopharmacology</i> , 2013 , 15, 50-7	5.8	14

(2006-2013)

23	Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin (1100-109) in sera of mice infected with bacteria. <i>Journal of Immunological Methods</i> , 2013 , 395, 54-62	2.5	9
22	Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. <i>Immunotherapy</i> , 2013 , 5, 497-511	3.8	29
21	Complexes of an alpha thymosin derivative with PR e and (IIm)Tc: structural analysis and initial biological evaluation. <i>Chemical Biology and Drug Design</i> , 2012 , 80, 545-53	2.9	3
20	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. <i>International Journal of Cancer</i> , 2012 , 130, 857-64	7.5	96
19	Polar constituents of Marrubium thessalum Boiss. & Heldr. (Lamiaceae) and their cytotoxic/cytostatic activity. <i>Phytotherapy Research</i> , 2012 , 26, 1800-6	6.7	23
18	Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 599-614	7.4	37
17	Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis. <i>In Vivo</i> , 2012 , 26, 395-402	2.3	47
16	Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 3110-2	2.9	6
15	Antidepressant pharmacotherapy: focus on sex differences in neuroimmunopharmacological crossroads. <i>Future Neurology</i> , 2010 , 5, 581-596	1.5	4
14	Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3929-38	5.6	18
13	Prothymosin alpha immunoactive carboxyl-terminal peptide TKKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. <i>Molecular Immunology</i> , 2009 , 46, 784-92	4.3	29
12	Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage?. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 1157-63	5.8	16
11	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. <i>Gynecologic Oncology</i> ,	4.9	71
10	2008 , 108, 421-7 Cytotoxicity and immunomodulating characteristics of labdane diterpenes from Marrubium cylleneum and Marrubium velutinum. <i>Phytochemistry</i> , 2007 , 68, 1587-94	4	22
9	Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation. <i>Proteomics</i> , 2007 , 7, 1814-24	4.8	37
8	Solid-phase synthesis of a peptide derivative of thymosin alpha1 and initial studies on its (99m)Tc-radiolabelling. <i>Chemical Biology and Drug Design</i> , 2007 , 70, 40-6	2.9	7
7	The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 1247-57	7.4	30
6	Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha. <i>Peptides</i> , 2006 , 27, 183-93	3.8	27

5	Serological detection of hepatitis B viral infection by a panel of solid-phase enzyme-linked immunosorbent assays (ELISA). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004 , 34, 811-22	3.5	12
4	A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragment. <i>Journal of Immunological Methods</i> , 2002 , 268, 141-8	2.5	10
3	HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. <i>International Journal of Cancer</i> , 2002 , 98, 864-72	7.5	34
2	Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. <i>Journal of Immunology</i> , 2000 , 164, 3902-12	5.3	143
1	Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha. <i>Cancer Immunology, Immunotherapy</i> , 1999 , 48, 71-84	7.4	13